Safety of PD-1 Inhibitors in Squamous Non-Small Cell Lung Cancer

1 意见
administrator
administrator
07/14/23

The panelists, Benjamin Levy, MD; Edward S. Kim, MD, FACP; and Paul K. Paik, MD, identify patients with squamous non-small cell lung cancer who may benefit from immune checkpoint inhibitors and the management of any related toxicity.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个